Congress
Northeast GI Oncology Congress 2026
Overview
Boston, Massachusetts
Date / Time
Nov 19, 2026 – Nov 21, 2026
Save to
The whole field, in one conversation.
GI oncology is moving quickly across biomarkers, targeted therapies, immunotherapy, liquid biopsy, and new treatment modalities. NEGI 2026 is designed to connect those advances across disease areas—and to keep the patient perspective in the room.
The program moves from bench science and emerging investigators to multidisciplinary clinical practice, access, equity, quality of life, and patient-partnered research. Every participant shares the same track, creating space for ideas to travel across specialties.
Partners
Congress Leadership
Meet the Congress Leadership
Dr. Yelena Janjigian is Chief of the Gastrointestinal Oncology Service and the Carroll and Milton Petrie Chair at Memorial Sloan Kettering Cancer Center. A physician-scientist specializing in esophageal and stomach cancers, she leads clinical and translational research focused on biomarker-directed treatment, immunotherapy, and the development of new therapeutic strategies for upper GI malignancies.
Dr. Samuel Klempner is a gastrointestinal medical oncologist at Massachusetts General Hospital. His work uses molecular characterization to individualize care across GI cancers, with particular emphasis on gastroesophageal malignancies. He leads clinical trials and translational research evaluating targeted agents, immune therapies, and the mechanisms that shape treatment response and resistance.
Dr. Aparma R. Parikh is a gastrointestinal medical oncologist at Massachusetts General Hospital and Medical Director of the Center for Young Adult Colorectal Cancer. Her clinical and research work centers on colorectal cancer, including young-onset disease, liquid biopsy, and novel therapeutic approaches. She also directs Mass General’s Global Cancer Care Program, advancing equitable access to cancer care and technology.
Dr. Eileen O’Reilly is the Winthrop Rockefeller Endowed Chair of Medical Oncology at Memorial Sloan Kettering Cancer Center. She is Co-Director for Medical Initiatives at the David M. Rubenstein Center for Pancreatic Cancer Research and Section Head of Hepatopancreatobiliary and Neuroendocrine Cancers. Her work focuses on pancreatic and hepatobiliary malignancies, including molecularly and genetically informed treatment strategies.
Ms. Martha Raymond is the Founder and CEO of the GI Cancers Alliance and The Raymond Foundation. She has more than four decades of experience advocating for cancer patients and caregivers. Her work focuses on patient education, advocacy, and research into patient-reported outcomes, ensuring that patients’ voices and lived experiences inform cancer care. She also develops oncology programs in collaboration with academic institutions, industry, and global advocacy organizations.
Scientific Program
Boston · Thursday–Saturday, November 19–21, 2026 · Single track · No parallel sessions
Day One
The Bench & the Next Generation
Thursday, November 19, 2026
| 11:00 AM | Registration & arrival lunch |
| 12:00 PM | Welcome & the case for one room |
| 12:20 PM | Opening Keynote — The State of GI Oncology, 2026 Keynote The year targeting RAS, Claudin-18.2, and ctDNA stopped being aspirational. |
| 1:00 PM | Across Upper GI · Debate & Plenary I — ctDNA and MRD Across GI / Debate Opens with the debate “ctDNA should govern adjuvant decisions in GI cancers today” — Pro vs Con, audience vote before and after. Then the evidence across colorectal, gastroesophageal and pancreatic cancer: assays, MRD-guided trials, what is ready and what is not. 20-minute discussion. |
| 2:15 PM | Break |
| 2:45 PM | Origin Stories — How We Built the Drug Keynotes The scientists behind GI oncology’s newest approvals tell how the molecule was made: the idea, the dead ends, the breakthrough. Discovery only — the clinical data follow in Friday’s site plenaries. |
| 4:00 PM | Young Investigator Rapid-Fire Rapid-Fire Postdoc & fellow short talks with senior critique, scored toward the Early-Career Award. |
| 4:45 PM | Across GI · Translational Plenary II — The new modalities Across GI / Trans How the platforms work and why they fail in solid GI tumors: CAR-T and T-cell engagers, personalized mRNA vaccines, ADC design and resistance. Mechanism here; tumor-specific results on Friday. |
| 5:45 PM | Welcome Reception & Poster Walk Reception Posters, Scientist Rapid-Fire presenters, faculty, biotech and advocates in one room. |
Day Two
The Whole Field, One Room
Friday, November 20, 2026
| 8:00 AM | Coffee & mentorship tables Mentorship Fellows and early-career oncologists sit with faculty. |
| 8:30 AM | Upper GI · Case-Based Tumor Board Upper GI / Case Board Fellows present two gastroesophageal cases; live multidisciplinary board with audience polling. |
| 9:30 AM | Upper GI · Plenary — Gastroesophageal cancer: choosing between targets Upper GI CLDN18.2, HER2, FGFR2b and PD-L1 overlap in the same patients — how to sequence and combine, and why GEA resists IO. Short talks, then panel. |
| 10:30 AM | Upper GI · Debate II — “Perioperative immunotherapy is ready for routine practice in GEA” Upper GI / Debate Pro vs Con, audience vote before and after. |
| 11:15 AM | Break |
| 11:30 AM | Scientist Rapid-Fire — From Bench to Clinic Rapid-Fire Biopharma & translational scientists present their work and discuss one question: what can this bring to the clinic? Abstract-selected, 7-minute talk + 3-minute faculty discussion each, judged; the winner receives ASCO GI 2027 registration. |
| 12:15 PM | Lunch & poster viewing |
| 1:30 PM | Pancreas & Biliary · Plenary — RAS(ON) in the clinic; precision by default in biliary Pancreas & Biliary Pancreas: RAS(ON) inhibitor trial results, KRAS G12D, combinations and clinical resistance. Biliary: FGFR2, IDH1 and HER2 on a chemo-IO backbone — biology to bedside. Short talks, one case, panel. |
| 3:00 PM | Break |
| 3:15 PM | Lower GI · Plenary — Colorectal: new targets, new rules Lower GI dMMR organ preservation, MSS-IO, KRAS/BRAF/HER2-targeted therapy, early-onset colorectal cancer biology. Short talks, one case, panel. |
| 4:30 PM | Across GI · Lessons that travel Across GI / Panel Chairs of every site on what RAS, HER2, CLDN18.2 and ctDNA teach across GI cancers — and which trials should cross sites. |
| 5:30 PM | Adjourn · optional faculty dinner |
Day Three
The Patient at the Table
Saturday, November 21, 2026
| 8:30 AM | Coffee |
| 9:00 AM | Patients · Advocacy Plenary — Patient-partnered research in GI Patients / Advocacy Each partner brings one research question patients want answered. |
| 9:45 AM | Patients · Latest Approvals in GI Cancer — What They Mean Patients Daraxonrasib, zanidatamab, zolbetuximab, perioperative IO — honest benefit, in plain language with chairs. |
| 10:15 AM | Featured Lecture — Movement is medicine: does CHALLENGE apply beyond colon cancer? Featured Structured exercise as therapy after the CHALLENGE trial, and whether it should apply across every GI cancer. |
| 10:45 AM | Patients · When less is better — quality of life & financial toxicity Patients / Panel Treatment breaks, stopping well, cost — clinicians and advocates together. |
| 11:15 AM | Break |
| 11:30 AM | Meet the Chairs — Designing a GI trial that matters Young Investigators / Panel Young investigators meet the chairs. Each chair brings one idea or one practical tip: choosing the question, endpoints that matter to patients, working with advocates from day one, getting a first trial funded and open. Advocates and fellows on the panel; open floor. |
| 12:00 PM | In five years, most adjuvant therapy in GI cancer will be guided by ___? Future / Panel Audience vote first (ctDNA · tumor biomarkers · stage · patient choice), then the panel names the trials they are most looking forward to — one each, and why it could change practice. |
| 12:30 PM | Awards & Closing — the road to New York 2027 Award Early-Career Award, Scientist Rapid-Fire & Best Poster — ASCO / ASCO GI registration support. |
| 1:00 PM | Farewell lunch |
Partnership Opportunities
Partnership & Collaboration Opportunities
Shushan Hovsepyan
Senior Vice President, OncoDaily
Email: shushan.hovsepyan@oncodaily.com
Phone: +1 571 775 9710
Event-Related Inquiries
Inessa Mkhitaryan
Head of Global Events, OncoDaily
Email: inessa.mkhitaryan@oncodaily.com
General Inquiries
Email: info@oncodaily.com
